Patents by Inventor Avigdor Levanon

Avigdor Levanon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090220486
    Abstract: The present invention provides antibodies or fragments thereof that bind to cancer cells and is important in physiological phenomena, such as cell rolling and metastasis. Therapeutic and diagnostic methods and compositions using such antibody fragments thereof are also provided. The methods and compositions according to the present invention can be used in targeting therapeutic agents and in diagnosis, prognosis, and staging of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease. Also provided is a library of immunoglobulin binding domains having a diverse antigen-binding domain for complementary binding, wherein the library has diversity only in heavy chain CDR3.
    Type: Application
    Filed: January 8, 2008
    Publication date: September 3, 2009
    Inventors: Daniel Plaksin, Avigdor Levanon, Esther Szanton, Yocheved Hagay, Rachel Ben-Levy, Yael Nisgav, Yariv Kanfi
  • Publication number: 20070149768
    Abstract: The present invention is directed to a peptide or polypeptide comprising an Fv molecule, a construct thereof, a fragment of either, or a construct of a fragment having enhanced binding characteristics so as to bind selectively and/or specifically to a target cell in favor of other cells, wherein the binding selectivity or specificity is primarily determined by a first hypervariable region, and wherein the Fv is a scFv or a dsFv, and optionally having one or more tags. The enhanced binding is directed to a substantially exposed and/or over-expressed binding site on or in a target comprising a cell in favor of other cells on or in which the binding site is not substantially available and/or expressed. The invention is further directed to a method for isolating such peptides and polypeptides from a phage display library and to the nucleic acid molecules encoding them.
    Type: Application
    Filed: March 22, 2006
    Publication date: June 28, 2007
    Inventors: Yocheved Hagay, Janette Lazarovits, Rachel Guy, Orly Lifshitz, Esther Szanton, Avigdor Levanon, Daniel Plaksin, Tuvia Peretz
  • Patent number: 7132510
    Abstract: The present invention is directed to novel peptides and polypeptides that specifically bind to target cells and may have anti-cancer activity, especially blood-related cancers. The present invention includes a peptide or polypeptide comprising an Fv molecule, having a heavy variable chain comprising CDR3, CDR2 and CDR1 regions comprising the amino acid sequences SEQ ID NOS:8, 115 and 114, respectively.
    Type: Grant
    Filed: December 31, 2001
    Date of Patent: November 7, 2006
    Assignee: Bio-Technology General (Israel) Ltd.
    Inventors: Yocheved Hagay, Janette Lazarovits, Rachel Guy, Orly Lifshitz, Esther Szanton, Avigdor Levanon, Daniel Plaksin, Tuvia Peretz
  • Patent number: 7087722
    Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: August 8, 2006
    Assignee: Savient Pharmaceuticals, Inc.
    Inventors: Tikva Vogel, Avigdor Levanon, Moshe Werber, Rachel Guy, Amos Panet
  • Publication number: 20050266009
    Abstract: The present invention provides antibodies or fragments thereof that bind to co-receptor CCR5 or CXCR4.
    Type: Application
    Filed: June 27, 2005
    Publication date: December 1, 2005
    Inventors: Daniel Plaksin, Avigdor Levanon, Esther Szanton, Yocheved Hagay, Rachel Ben-Levy, Yael Nisgav, Yariv Kanfi
  • Publication number: 20050152906
    Abstract: The present invention provides antibodies that bind an epitope of PSGL-1 comprising the motif D-X-Y-D, wherein X represents any amino acid or the covalent linkage between D and Y, and Y is sulfated, which antibody can be complexed with one or more copies of an agent. The antibodies of the invention can be used in a method of inducing antibody-dependent cell cytotoxicity and/or stimulating natural killer (NK) cells or T cells. In addition, by administering these antibodies to a patient in need thereof, a method of inducing cell death is provided. A method of preventing infection by a virus (e.g., HIV) by administering to a patient in need thereof an antibody of the present invention is also provided. The, present invention also provides a method of introducing an agent into a cell that expresses sulfated PSGL-1 by coupling or complexing an agent to an antibody of the present invention and administering the complex to the cell.
    Type: Application
    Filed: June 30, 2004
    Publication date: July 14, 2005
    Inventors: Avigdor Levanon, Tikva Vogel, Daniel Plaksin, Tuvia Peretz, Boaz Amit, Lena Cooperman, Yocheved Hagay, Esther Szanton, Yariv Kanfi, Rachel Ben-Levy, Tali Szrajber
  • Publication number: 20050069955
    Abstract: The present invention provides antibodies or fragments thereof that bind to cancer cells and is important in physiological phenomena, such as cell rolling and metastasis. Therapeutic and diagnostic methods and compositions using such antibody fragments thereof are also provided. The methods and compositions according to the present invention can be used in targeting therapeutic agents and in diagnosis, prognosis, and staging of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease. Also provided is a library of immunoglobulin binding domains having a diverse antigen-binding domain for complementary binding, wherein the library has diversity only in heavy chain CDR3.
    Type: Application
    Filed: June 30, 2004
    Publication date: March 31, 2005
    Inventors: Daniel Plaksin, Avigdor Levanon, Esther Szanton, Yocheved Hagay, Rachel Ben-Levy, Yael Nisgav, Yariv Kanfi
  • Publication number: 20040208877
    Abstract: The present invention provides antibodies or fragments thereof that bind to cancer cells and are important in physiological phenomena, such as cell rolling and metastasis. Therapeutic and diagnostic, prognostic or staging methods and compositions using such antibodies or fragments thereof are also provided. The methods and compositions according to the present invention can be used in diagnosis of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease.
    Type: Application
    Filed: June 30, 2003
    Publication date: October 21, 2004
    Inventors: Avigdor Levanon, Rachel Ben-Levy, Daniel Plaksin, Esther Szanton, Yocheved Hagai, Hagit Hoch Mar-Chaim
  • Publication number: 20040202665
    Abstract: The present invention relates to compositions utilizing an agent and an antibody, or fragment thereof. In these compositions, the agents, including agents such as anti-cancer, anti-metastasis, anti-leukemia, anti-disease, anti-adhesion, anti-thrombosis, anti-restenosis, anti-autoimmune, anti-aggregation, anti-bacterial, anti-viral, and anti-inflammatory agents, can be complexed or combined with or conjugated to the antibodies, or fragments thereof. In addition, the agent and/or the antibody, or fragment thereof, can be present in the composition in a sub-clinical amount, which is an amount that is less than the amount of the agent generally found to be clinically effective when the agent is administered alone. Preferably, in these compositions of the present invention, the agent is an anthracycline or a derivative thereof, e.g., doxorubicin (adriamycin) or a derivative thereof.
    Type: Application
    Filed: June 30, 2003
    Publication date: October 14, 2004
    Inventors: Janette Lazarovits, Abraham Nimrod, Hagit Hoch Mar-Chaim, Avigdor Levanon
  • Publication number: 20040073011
    Abstract: The present invention is directed to a peptide or polypeptide comprising an Fv molecule, a construct thereof, a fragment of either, or a construct of a fragment having enhanced binding characteristics so as to bind selectively and/or specifically to a target cell in favor of other cells, wherein the binding selectivity or specificity is primarily determined by a first hypervariable region, and wherein the Fv is a scFv or a dsFv, and optionally having one or more tags. The enhanced binding is directed to a substantially exposed and/or over-expressed binding site on or in a target comprising a cell in favor of other cells on or in which the binding site is not substantially available and/or expressed. The invention is further directed to a method for isolating such peptides and polypeptides from a phage display library and to the nucleic acid molecules encoding them.
    Type: Application
    Filed: December 31, 2001
    Publication date: April 15, 2004
    Inventors: Yocheved Hagay, Janette Lazarovits, Rachel Guy, Orly Lifshitz, Esther Szanton, Avigdor Levanon, Daniel Plaksin, Tuvia Peretz
  • Publication number: 20040001822
    Abstract: The present invention provides epitopes present on cancer cells and important in physiological phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and compositions using antibodies capable of binding to the epitopes are provided. Methods and compositions according to the present invention can be used in diagnosis of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease.
    Type: Application
    Filed: December 31, 2001
    Publication date: January 1, 2004
    Inventors: Avigdor Levanon, Yocheved Hagay, Daniel Plaksin, Tikva Vogel, Abraham Nimrod, Hagit Mar-Haim, Esther Szanthon, Tamar Richter, Boaz Amit, Lena Cooperman, Tuvia Peretz, Janette Lazarovits
  • Publication number: 20040001839
    Abstract: The present invention provides epitopes present on cancer cells and important in physiological phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and compositions using antibodies capable of binding to the epitopes are provided.
    Type: Application
    Filed: December 31, 2001
    Publication date: January 1, 2004
    Inventors: Avigdor Levanon, Yocheved Hagay, Daniel Plaksin, Tikva Vogel, Abraham Nimrod, Hagit Mar-Haim, Ester Szanthon, Tamar Richter, Boaz Amit, Lena Cooperman, Tuvia Peretz, Janette Lazarovits
  • Publication number: 20040002450
    Abstract: The present invention provides epitopes present on cancer cells and important in physiological phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and compositions using antibodies capable of binding to the epitopes are provided.
    Type: Application
    Filed: December 31, 2001
    Publication date: January 1, 2004
    Inventors: Janette Lazarovits, Yocheved Hagay, Daniel Plaksin, Tikva Vogel, Abraham Nimrod, Hagit Mar-Ham, Ester Szanthon, Tamar Richter, Boaz Amit, Lena Cooperman, Tuvia Peretz, Avigdor Levanon
  • Patent number: 6211341
    Abstract: The present invention provides an antibody which specifically reacts with an epitope of a polypeptide comprising the amino acid sequence X-Y-CYS GLN GLU GLU GLU CYS PRO ASP PRO TYR LEU CYS SER PRO VAL THR ASN ARG CYS GLU CYS THR PRO VAL LEU CYS ARG MET TYR CYS LYS PHE TRP ALA LYS ASP GLU LYS GLY CYS GLU ILE CYS LYS CYS GLU GLU LEU CYS GLN ASN GLN ASN CYS THR LYS ASP MET LEU CYS SER SER VAL THR ASN ARG CYS ASP CYS GLN ASP PHE LYS CYS PRO GLN SER TYR CYS-Z (SEQ. ID NO. 1) wherein X is MET or absent; Y is 0-28 amino acids of the sequence LYS MET CYS TRP ASN LYS GLY CYS PRO CYS GLY GLN ARG CYS ASN LEU HIS ARG ASN GLU CYS GLU VAL ILE ALA GLU ASN ILE GLU, (SEQ. ID NO. 2) with the proviso that if part of the sequence is present, it is a carboxy-terminal part of the sequence including the carboxy-terminal GLU and wherein Val may be preceded by Gly; and Z is absent or all or a part of the sequence Pro110-Lys156 shown in FIG. 7 (SEQ. ID NO.
    Type: Grant
    Filed: January 11, 1999
    Date of Patent: April 3, 2001
    Assignee: Bio-Technology General Corp.
    Inventors: Elisha P. Zeelon, Moshe M. Werber, Avigdor Levanon
  • Patent number: 6121426
    Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.
    Type: Grant
    Filed: August 11, 1997
    Date of Patent: September 19, 2000
    Assignee: Bio-Technology General Corp.
    Inventors: Tikva Vogel, Avigdor Levanon, Moshe Werber, Rachel Guy, Amos Panet
  • Patent number: 6054291
    Abstract: An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.
    Type: Grant
    Filed: June 9, 1997
    Date of Patent: April 25, 2000
    Assignee: Bio-Technology General Corp.
    Inventors: Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel
  • Patent number: 5965383
    Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus-or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: October 12, 1999
    Assignee: Bio-Technology General Corp.
    Inventors: Tikva Vogel, Avigdor Levanon, Moshe Werber, Rachel Guy, Amos Panet
  • Patent number: 5869616
    Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: February 9, 1999
    Assignee: Bio-Technology General Corp.
    Inventors: Tikva Vogel, Avigdor Levanon, Moshe M. Werber, Rachel Guy, Amos Panet, Jacob Hartman, Hadassa Shaked
  • Patent number: 5863534
    Abstract: A novel polypeptide derived from the leech Hirudo medicinalis was found to be able to inhibit Factor Xa thereby reducing the extent of blood coagulation. The polypeptide is useful in treating conditions of excessive blood coagulation. A recombinant organism containing cDNA encoding the polypeptide has been deposited in the ATCC under Accession No. 69134. Recombinant microorganisms able to produce the polypeptide have been deposited in the ATCC under Accession Nos. 69135, 69137 and 69269.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 26, 1999
    Assignee: Bio-Technology General Corp.
    Inventors: Elisha P. Zeelon, Moshe M. Werber, Avigdor Levanon
  • Patent number: 5858970
    Abstract: A novel polypeptide derived from the leech Hirudo medicinalis was found to be able to inhibit Factor Xa thereby reducing the extent of blood coagulation. The polypeptide is useful in treating conditions of excessive blood coagulation. A recombinant organism containing cDNA encoding the polypeptide has been deposited in the ATCC under Accession No. 69134. Recombinant microorganisms able to produce the polypeptide have been deposited in the ATCC under Accession Nos. 69135, 69137 and 69269.
    Type: Grant
    Filed: January 7, 1997
    Date of Patent: January 12, 1999
    Assignee: Bio-Technology General Corp.
    Inventors: Elisha P. Zeelon, Moshe M. Werber, Avigdor Levanon